Indication
Hepatobiliary
1 clinical trial
1 product
Clinical trial
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor HistologyStatus: Active (not recruiting), Estimated PCD: 2023-01-25
Product
Trastuzumab deruxtecan